Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Department of Medicinal Chemistry, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Mycoses. 2021 Nov;64(11):1308-1316. doi: 10.1111/myc.13277. Epub 2021 Apr 3.
Candida auris is an emerging and drug-resistant pathogen. Drug combination is a promising approach against such pathogens. This study was conducted to provide an overview of all the studied drug combinations against C. auris. Relevant articles reporting results of any drug/non-drug combinations against C. auris were found by a systematic search in PubMed, Scopus and Web of Science (ISI), and in Google Scholar up to 1 October 2020. From 187 articles retrieved in the primary search, 23 met the inclusion criteria. In total, 124 different combinations including antifungal with antifungal (45), antifungal with other antimicrobials (11), antifungal with non-antimicrobials (32), antifungal with natural compounds (25) and between natural compounds (11) have been reported. Complete or partial synergistic effects have been reported for 3 out of 45 (6.67%) combinations of two antifungal agents, 8 out of 11 (72.73%) combinations involving antifungal agents and antimicrobials, 15 out of 32 (46.88%) of combinations between antifungal agents with non-antimicrobials, 16 out of 25 (64%) of combinations involving antifungal agents and natural compounds, and 3 out of 11 (22.27%) of combinations involving multiple natural compounds. Antagonistic interactions have been reported for 1 out of 32 (3.13%) and 8 out of 25 (32%) of combinations between antifungal drugs with non-antimicrobials and with natural compounds, respectively. Different drugs/compounds could potentiate the activity of antifungal drugs using this approach. However, despite the availability of this promising initial data, many more studies will be required to elucidate whether favourable interactions observed in vitro might translate into tangible clinical benefits.
耳念珠菌是一种新兴的、耐药的病原体。药物联合是对抗此类病原体的一种有前途的方法。本研究旨在提供所有针对耳念珠菌的研究药物组合的概述。通过在 PubMed、Scopus 和 Web of Science（ISI）以及 Google Scholar 中进行系统搜索，查找截至 2020 年 10 月 1 日报道任何药物/非药物组合对抗耳念珠菌的结果的相关文章。从初步搜索中检索到的 187 篇文章中，有 23 篇符合纳入标准。总共报告了 124 种不同的组合，包括抗真菌药物与抗真菌药物（45 种）、抗真菌药物与其他抗菌药物（11 种）、抗真菌药物与非抗菌药物（32 种）、抗真菌药物与天然化合物（25 种）以及天然化合物之间（11 种）的组合。报道了 45 种两种抗真菌药物组合中有 3 种（6.67%）完全或部分协同作用，11 种涉及抗真菌药物和抗菌药物的组合中有 8 种（72.73%），32 种抗真菌药物与非抗菌药物之间的组合中有 15 种（46.88%），25 种涉及抗真菌药物和天然化合物的组合中有 16 种（64%），11 种涉及多种天然化合物的组合中有 3 种（22.27%）。报道了抗真菌药物与非抗菌药物和天然化合物之间的组合分别有 1 种（3.13%）和 8 种（32%）存在拮抗相互作用。通过这种方法，不同的药物/化合物可以增强抗真菌药物的活性。然而，尽管有这些有希望的初步数据，仍需要进行更多的研究来阐明体外观察到的有利相互作用是否可以转化为实际的临床益处。
